The Lancet is the world's leading general medical journal and specialty journals in Oncology, Neurology and Infectious Diseases. Has increased it's coverage of GVAX quite a bit. This should help give the cancer program street credibility and attract more longs.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.